Alnylam Pharmace. buy Evercore ISI
Start price
11.09.25
/
50%
€399.10
Target price
11.09.26
€440.26
Performance (%)
-15.16%
Price
12.12.25
€338.60
Summary
This prediction is currently active. The price of Alnylam Pharmace. has decreased since the start of the prediction. Compared to the start price this results in a performance of -15.16%. This prediction currently runs until 11.09.26. The prediction end date can be changed by Evercore_ISI at any time. Evercore_ISI has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | -13.930% | -13.930% |
| iShares Core DAX® | 0.734% | -0.964% |
| iShares Nasdaq 100 | -2.686% | -2.409% |
| iShares Nikkei 225® | -2.261% | -4.038% |
| iShares S&P 500 | -1.346% | -1.510% |
Comments by Evercore_ISI for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Evercore ISI from $280.00 to $515.05. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by Evercore_ISI for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€221.10
25.06.24
25.06.24
€242.92
25.06.25
25.06.25
25.69%
26.06.25
26.06.25
